MethylGene Reports First Quarter 2013 Financial Results
5/13/2013 11:03:31 AM
More...
|
MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ
5/9/2013 9:56:27 AM
More...
|
MethylGene Presents Preclinical Data on MG516 at the American Association for Cancer Research Annual Meeting
4/8/2013 11:56:09 AM
More...
|
MethylGene Reports Results of Phase 2 Trial of MGCD290
3/18/2013 12:04:55 PM
More...
|
MethylGene Announces Management Changes
3/14/2013 11:51:34 AM
More...
|
MethylGene Reports Fourth Quarter and Full Year 2012 Financial Results
3/13/2013 10:15:14 AM
More...
|
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
2/19/2013 11:45:43 AM
More...
|
MethylGene Completes Enrollment in Phase 2 Trial of MGCD290
12/19/2012 11:41:29 AM
More...
|
MethylGene to Present at the Piper Jaffray 24th Annual Healthcare Conference
11/21/2012 12:14:06 PM
More...
|
MethylGene Closes $26.1 Million Private Placement
11/21/2012 8:23:36 AM
More...
|
|